CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study

Zhong,Weixia; Chen,Weiwei; Zhang,Dexian; Sun,Jujie; Li,Yuhui; Zhang,Jianbo; Gao,Yongsheng; Zhou,Wuyuan; Li,Sheng

doi:10.3892/etm.2012.631

CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study

Authors:
- Weixia Zhong
- Weiwei Chen
- Dexian Zhang
- Jujie Sun
- Yuhui Li
- Jianbo Zhang
- Yongsheng Gao
- Wuyuan Zhou
- Sheng Li
View Affiliations

Affiliations: Shandong Tumor Hospital, Jinan 250117, P.R. China, Jinan Central Hospital, Jinan 250001, P.R. China
Published online on: July 4, 2012 https://doi.org/10.3892/etm.2012.631
Pages: 363-369

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is one of the most lethal types of cancer, and curative resection is only applicable to potentially limited cases due to early metastasis and local invasion. This study reports the influence of CXCL12 and its receptor CXCR4 on the progression of pancreatic cancer and highlights the correlation between the CXCL12/CXCR4 axis and the organ-specific metastasis of pancreatic adenocarcinoma (PAC). A total of 34 patients with pancreatic cancer participated in the current study. The expression of CXCL12 and CXCR4 in cancerous tissues, paracancerous tissues, normal pancreas and lymph nodes surrounding the pancreas were investigated using immunohistochemistry and RT-PCR; furthermore, their relationship with clinicopathological factors was explored (PV9000 method). The positive rate of CXCL12 protein was 13.3% (4/30), the positive rate of CXCR4 protein was 80% (24/30) in tumor tissues. Additionally, a significant correlation between the expression pattern of the CXCL12/CXCR4 axis with lymph node metastasis was identified (P<0.05), excluding gender, age, tumor node metastasis (TNM) stage and differentiation (all P>0.05). Also, the positive rate of CXCL12 protein was 50% (15/30), the positive rate of CXCR4 protein was 73.3% (22/30) in the lymphocytes in lymph nodes surrounding the pancreas. Furthermore, we found that CXCL12 and CXCR4 expression in paratumorous vessels and neural tissue were significantly strongly positive. The paratumorous vessels and neural tissue with positive CXCL12 and CXCR4 expression were invaded by CXCL12-positive pancreatic cancer cells. The chemotactic interaction between CXCR4 and its ligand CXCL12 may be a critical event during the progression of pancreatic cancer. The CXCL12/CXCR4 axis plays an important role in the progression and organ-specific metastasis of pancreatic adenocarcinoma.

View Figures

View References

1.	Oh JW, Olman M and Benveniste EN: CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4-positive astroglioma cells. Biol Pharm Bull. 32:573–577. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Sallusto F, Mackay CR and Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 18:593–620. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Birk D, Fortnagel G, Formentini A and Beger HG: Small carcinoma of the pancreas. Factors of prognostic relevance. J Hepatobiliary Pancreat Surg. 5:450–454. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Salmaggi A, Maderna E, Calatozzolo C, et al: CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther. 8:1608–1614. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Hassan S, Ferrario C, Saragovi U, et al: The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol. 175:66–73. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Welch DR and Goldberg SF: Molecular mechanisms controlling human melanoma progression and metastasis. Pathobiology. 65:311–330. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Lu C and Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 120:1281–1288. 1993.PubMed/NCBI
8.	Wu X, Lee VC, Chevalier E and Hwang ST: Chemokine receptors as targets for cancer therapy. Curr Pharm Des. 15:742–757. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Kato M, Kitayama J, Kazama S and Nagawa H: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 5:R144–150. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S and Shim H: CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 359:716–722. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Morales J, Homey B, Vicari AP, et al: CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA. 96:14470–14475. 1999. View Article : Google Scholar : PubMed/NCBI
12.	Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Campbell JJ and Butcher EC: Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 12:336–341. 2000. View Article : Google Scholar : PubMed/NCBI
14.	Butcher EC, Williams M, Youngman K, Rott L and Briskin M: Lymphocyte trafficking and regional immunity. Adv Immunol. 72:209–253. 1999. View Article : Google Scholar : PubMed/NCBI
15.	Klein RS, Rubin JB, Gibson HD, et al: SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development. 128:1971–1981. 2001.PubMed/NCBI
16.	Peled A, Petit I, Kollet O, et al: Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:845–848. 1999. View Article : Google Scholar : PubMed/NCBI
17.	Eash KJ, Means JM, White DW and Link DC: CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood. 113:4711–4719. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Salogni L, Musso T, Bosisio D, et al: Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood. 113:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Monterrubio M, Mellado M, Carrera AC and Rodriguez-Frade JM: PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion. Biochem Biophys Res Commun. 388:199–204. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Sozzani S, Allavena P, D’Amico G, et al: Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol. 161:1083–1086. 1998.PubMed/NCBI
21.	Bottazzi B, Walter S, Govoni D, Colotta F and Mantovani A: Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol. 148:1280–1285. 1992.
22.	Seo KS, Park JY, Davis WC, et al: Superantigen-mediated differentiation of bovine monocytes into dendritic cells. J Leukoc Biol. 85:606–616. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Leng Q, Nie Y, Zou Y and Chen J: Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development. BMC Immunol. 9:512008. View Article : Google Scholar : PubMed/NCBI
24.	Sasaki K, Natsugoe S, Ishigami S, et al: Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep. 21:65–71. 2009.PubMed/NCBI
25.	Xu Q, Yuan X, Xu M, et al: Chemokine CXC receptor 4-mediated glioma tumor tracking by bone marrow – derived neural progenitor/stem cells. Mol Cancer Ther. 8:2746–2753. 2009.PubMed/NCBI
26.	Uchida D, Onoue T, Begum NM, et al: Vesnarinone downregulates CXCR4 expression via upregulation of Kruppel-like factor 2 in oral cancer cells. Mol Cancer. 8:622009. View Article : Google Scholar : PubMed/NCBI
27.	Mirisola V, Zuccarino A, Bachmeier BE, et al: CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer. 45:2579–2587. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Sauter ER and Herlyn M: Molecular biology of human melanoma development and progression. Mol Carcinog. 23:132–143. 1998. View Article : Google Scholar : PubMed/NCBI
29.	Vandercappellen J, Van Damme J and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V and Dwinell MB: Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene. 25:4986–4997. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI